Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trimel Pharmaceuticals has achieved key milestones in its female sexual dysfunction program of its no-touch bioadhesive intranasal gel product Tefina (TBS-2) for the treatment of Female Anorgasmia.
Subscribe to our email newsletter
The results from the TBS-2 Phase II Vibrotactile Stimulation (VTS) study demonstrated that Tefina had met all study endpoints.
The VTS study measured the occurrence of, time to reach, and the quality of the orgasm, as compared to placebo.
The results indicate that the separation between placebo and active drug demonstrates a significantly positive finding for Tefina.
The company plans to initiate its second Phase II study of Anorgasmia.
The company has filed Tefina with US Patent and Trademark Office under TBS-2 trade name.
Trimel chairman and CEO Bruce Brydon said the positive conclusion of Phase II VTS study denotes support for their decision to pursue a use as required product for women experiencing Anorgasmia.